Protected: Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
This content is password-protected. To view it, please enter the password below. Password:
Browsing: Boehringer Ingelheim
Trending
- Microplastics in intravenous infusions: emerging health concerns for medical practitioners
- Interval breast cancer: understanding risks and the need for enhanced screening
- Prostate cancer and erectile function: NeuroSAFE technique enhances postoperative outcomes in robot-assisted radical prostatectomy
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
- ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
- ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
- ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
- ASCO 2026: Fasting before and after chemo may help improve treatment response for some people with ovarian cancer
- ASCO 2026: Less cognitive decline with darolutamide treatment than enzalutamide in people with advanced prostate cancer
- ASCO 2026: Trial tests virus-immunotherapy combination for neuroendocrine tumours
- ASCO 2026: New AI tool may help personalise multiple myeloma treatment
